Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
CD8(+) T cells secreting type 2 lymphokines are defective in protection against viral infection.
Cell Immunol. 2000 May 25;202(1):13-22. Unique Identifier : AIDSLINE MED/20334541 Wirth S; van den Broek M; Frossard CP; Hugin AW; Leblond I; Pircher H; Hauser C; Allergy Unit, Division of Immunology and Allergy, Hopital; Cantonal Universitaire, Geneva, Switzerland.
Abstract:
Effector T cells secreting type 1 and/or type 2 lymphokines (Tc1, Tc0, Tc2) were generated in vitro from CD8(+) T cells of mice with a transgenic TCR recognizing lymphocytic choriomeningitis virus (LCMV) glycoprotein to compare their effector function in vitro and in vivo. Tc1, Tc2, and Tc0 showed similar Fas- and perforin-mediated cytotoxicity in vitro. Upon adoptive transfer, Tc2 and Tc0 effectors were less efficient than Tc1 at controlling LCMV or recombinant vaccinia virus expressing the LCMV glycoprotein in vivo. Tc2 and Tc0 had decreased surface VLA-4 density and deficient activation-induced LFA-1/ICAM-1-dependent homotypic adhesion in vitro. Therefore, the reduced antiviral activity in vivo of Tc2 and Tc0 compared with Tc1 is not due to reduced cytotoxic activity or IFN-gamma secretion but may be explained by defective homing to the target organ due to decreased expression and/or lower activity of adhesion molecules. Copyright 2000 Academic Press.
Keywords: JOURNAL ARTICLE Adoptive Transfer Animal Chemotaxis, Leukocyte Cytotoxicity Tests, Immunologic CD8-Positive T-Lymphocytes/*VIROLOGY Integrins Intercellular Adhesion Molecule-1 Interleukin-4/SECRETION Interleukin-5/SECRETION Lymphocyte Function-Associated Antigen-1 Lymphocytic Choriomeningitis Virus/*IMMUNOLOGY Lymphokines/*SECRETION Mice Mice, Inbred C57BL Mice, Transgenic Receptors, Antigen, T-Cell/GENETICS Receptors, Lymphocyte Homing Support, Non-U.S. Gov't 001030
A00A1086
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from
Elton John AIDS Foundation,
the National Library of Medicine,
and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.